Six-membered heterocycles useful as serine protease inhibitors

Details Six-membered heterocycles useful as serine protease inhibitors Six-membered heterocycles useful as serine protease inhibitors

2008-09-30

2008-09-30

Davis, Zinna N (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S357000, C546S268100, C546S336000

Reexamination Certificate

active

11151627

ABSTRACT:
The present invention provides compounds of Formula (I):or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, X1, X2, X3, X4, and X5are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

REFERENCES:
patent: 5622982 (1997-04-01), Schuster et al.
patent: 6448281 (2002-09-01), Beaulieu et al.
patent: 6465493 (2002-10-01), Burgess et al.
patent: 6503933 (2003-01-01), Maloney et al.
patent: 2003/0153604 (2003-08-01), Dankulich et al.
patent: 2003/0225131 (2003-12-01), Burgey et al.
patent: 2004/0214888 (2004-10-01), Matsuura et al.
patent: 2004/0220206 (2004-11-01), Smallheer et al.
patent: 2004/0235847 (2004-11-01), Quan et al.
patent: 2005/0228000 (2005-10-01), Smallheer et al.
patent: 2005/0282805 (2005-12-01), Hangeland et al.
patent: 2006/0154915 (2006-07-01), Corte et al.
patent: WO 92/02513 (1992-02-01), None
patent: WO 200071512 (2000-11-01), None
patent: WO 200127079 (2001-04-01), None
patent: WO 02/44273 (2002-05-01), None
patent: WO 02/064559 (2002-08-01), None
patent: WO 03/035076 (2003-05-01), None
patent: WO 2003062222 (2003-07-01), None
patent: WO 2004/014844 (2004-02-01), None
patent: WO 2004/019868 (2004-03-01), None
patent: WO 2005/007627 (2005-01-01), None
patent: WO 2005/063690 (2005-07-01), None
patent: WO 2005/085198 (2005-09-01), None
U.S. Appl. No. 11/610,027, Pinto et al.
U.S. Appl. No. 11/151,667, filed Jun. 13, 2005, Hangeland et al.
Desai et al., “Synthesis and biological activity of cyanopyridine, isoxazole and pyrazoline derivatives having thymol moiety,” Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, vol. 42B(2), pp. 382-385, 2003.
Artis et al., “Structure-Based Design of Six Novel Classes of Nonpeptide Antagonists of the Bradykinin B2Receptor,” Bioorganic & Medicinal Chemistry Letters, vol. 10, pp. 2421-2425, 2000.
Galiani, D., “Activation of Factor IX by Factor XIa”,Trends in Cardiovascular Medicine, vol. 10, No. 5, 2000. pp. 198-204.
Bouma, B.N. et al., “Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)”,Thrombosis. Research, 2001, 101, pp. 329-354.
Gailani, D., “Gene Targeting in Hemostasis. Factor XI”,Frontiers in Bioscience, 2001, 6, pp. d201-d207.
Gailani, D., et al., “A murine model of factor XI deficiency”,Blood Coagulation and Fibrinolysis, 1997, vol. 8, pp. 134-144.
Minnema, M.C., et al., “Activation of Clotting Factors XI and IX in Patients with Acute Myocardial Infarction”,Arterioscler. Thromb. Vasc. Biol., 2000, 20, pp. 2489-2493.
Murakami, T., et al., “Evaluation of Factor XIa-α1-Antitrypsin in Plasma, a Contact Phase-Activated Coagulation Factor-Inhibitor Complex, in Patients With Coronary Artery Disease”,Arterioscler. Thromb. Vasc. Biol., 1995, 15, pp. 1107-1113.
Meijers, J.C.M., et al., “High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis”,N. Engl. J. Med., 2000, vol. 342, No. 10, pp. 696-701.
Walsh, P.N., “Platelets and Factor XI Bypass the Contact System of Blood Coagulation”,Thromb. Haemostasis. 82(2), pp. 234-242, 1999.
Colman, R. Contact Activation Pathway: Inflammatory, Fibrinolytic, Anticoagulant, Antiadhesive, and Antiangiogenic Activities,Hemostasis and thrombosis: basic principles and clinical practice, Lippincott Williams & Wilkins, 2001, pp. 103-122.
Schmaier, A.H., “Contact Activation”,Thrombosis and Hemorrhage, Williams & Wilkins, 1998, pp. 105-128.

Affiliated with

Also associated with

Rating

Six-membered heterocycles useful as serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Six-membered heterocycles useful as serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Six-membered heterocycles useful as serine protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3908874